How much does a box of osimertinib cost at the latest market price?

Osimertinib is an oral, irreversible third-generation EGFR-TKI that mainly targets EGFR sensitive mutations and T790M resistance mutations. It has been widely used in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) and is suitable for initial treatment, recurrence and adjuvant treatment after surgery. Its indications include first-line treatment of EGFR Exon 19 deletion or L858R mutation-positive patients, and subsequent treatment of T790M mutation-positive patients who have progressed after receiving first- or second-generation TKI therapy.

In addition, as of 2021, osimertinib has also been approved for use in postoperative adjuvant therapy to extend disease-free survival. In the domestic market, the original drug of Osimertinib (trade name: Tagrisso) is produced by AstraZeneca. The mainstream specifications are 80mg*30 tablets and 40mg*30 tablets. The price per box is approximately RMB 4,000-6,000, which fluctuates slightly depending on the hospital procurement channel. Since the drug has been included in the national medical insurance catalog, eligible patients can enjoy a higher proportion of medical insurance reimbursement, and the actual price paid can be reduced to less than 30% of the original price, which greatly reduces the burden on families. In overseas markets, the price of osimertinib is relatively high. The price in the United States, Europe and other places generally exceeds 10,000 US dollars per box. However, the price also fluctuates due to different medical insurance systems.

At the same time, countries such as Laos and Bangladesh have launched generic drugs of osimertinib, with significantly lower prices.80mg*30 tablets are priced at about RMB 800, and some channels are even lower, providing patients with limited economic conditions with a more accessible option. However, when choosing generic drugs, patients should ensure that the drug is sourced from formal sources and consult professional doctors to ensure efficacy and safety. At present, with the increasing global acceptance of targeted therapies, osimertinib has also accelerated the approval process of generic drugs in many countries. Future market competition is expected to further stabilize prices and improve patient benefits.

Reference materials:https://go.drugbank.com/drugs/DB09330